- Construction starts this year, with the first mRNA vaccine produced in 2025.
- The UK government invested £395 million to enhance vaccine manufacturing.
- The centre will develop mRNA vaccines for COVID-19, flu, RSV, and other diseases.
- Moderna will conduct a large share of its clinical trials in the UK.
New mRNA Innovation and Technology Centre
NHS patients will benefit from next-generation mRNA vaccines and treatments through a new manufacturing and research centre in the UK. This facility will develop advanced mRNA vaccines for various respiratory diseases, including COVID-19, flu, and RSV, ensuring rapid response to emerging health threats.
Construction and Production Timeline
Construction of the centre is expected to begin this year, with the first mRNA vaccine produced in the UK by 2025. The facility will also create jobs and enhance the UK's ability to respond to future pandemics by scaling up production quickly during health emergencies.
Government Investment and Strategic Partnership
The UK government has invested £395 million to boost vaccine manufacturing capabilities since the pandemic's onset. This strategic partnership with Moderna builds on the collaboration formed during the pandemic, aiming to secure a consistent supply of vaccines and support the UK's status as a science superpower.
Research and Development Focus
The new centre will focus on unlocking the potential of mRNA technology, which has proven effective during the pandemic. It aims to develop revolutionary treatments for diseases such as cancer, dementia, and heart disease, benefiting NHS patients and people worldwide.
Clinical Trials and Future Capabilities
Moderna plans to expand its presence in the UK by investing in research and development and conducting a significant portion of its clinical trials locally. The partnership supports the UK's Life Sciences Vision, aiming to establish the country as a leading global hub for life sciences and enhance its domestic vaccine resilience.
